This Week at PeptideChat
Our rotating picks — what we're highlighting in peptides, stacks, vendors, and the latest research.
Peptide of the Week
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Stack of the Week
CagriSema
A combination of a long-acting amylin analog with a GLP-1 agonist to enhance satiety and appetite suppression for weight loss.
Vendor of the Week
Peptide Sciences
A long-running research-peptide supplier often cited for third-party testing and certificates of analysis. Always verify current COAs and purity yourself — an educational spotlight, not an endorsement.
Hottest New Peptides
Petrelintide
Petrelintide is a long-acting amylin analog in phase 2/3 development for weight management, notable for producing meaningful weight loss with markedly less gastrointestinal burden than incretin-based drugs.
Amycretin (Zenagamtide)
Amycretin — now assigned the international nonproprietary name zenagamtide — is a single peptide that agonizes both the GLP-1 and amylin receptors, combining two distinct appetite pathways in one molecule.
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Maridebart Cafraglutide (MariTide)
MariTide is a once-monthly peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor — the opposite GIP strategy from tirzepatide, and the most mechanistically unusual drug in late-stage obesity development.